Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Rhea-AI Summary
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based protein expression system, has scheduled the release of its fiscal year 2024 financial results for March 17, 2025.
The company will host a conference call and webcast at 8:30 a.m. EDT on the same day, where management will discuss financial results and provide updates on corporate and regulatory developments. The call will feature a Call me™ functionality for easy access, and a replay will be available for two weeks on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – PLX
On the day this news was published, PLX declined 0.43%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: | Monday, March 17, 2025 |
Time: | 8:30 a.m. Eastern Daylight Time (EDT) |
Toll Free: | 1-877-423-9813 |
International: | 1-201-689-8573 |
Israeli Toll Free: | 1-809-406-247 |
Conference ID: | 13752080 |
Call me™: |
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
Company Link: | |
Webcast Link: | |
Conference ID: | 13752080 |
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2024-financial-and-business-results-on-march-17-2025-302396854.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics (PLX) release its fiscal year 2024 financial results?
What time is PLX's fiscal year 2024 earnings conference call scheduled?
How long will the replay of PLX's fiscal year 2024 earnings call be available?
What special feature does PLX offer for their earnings call access?
